SHP2 inhibitors TNO155 and RMC-4550 target the first druggable phosphatase in cancer. Allosteric mechanism, synergy with KRAS G12C inhibitors, and clinical development.
Glutaminase inhibitors CB-839 and BPTES targeting cancer’s glutamine addiction. How GLS1 inhibition disrupts cancer cell biosynthesis and metabolism.
IDH1 and IDH2 inhibitors targeting oncometabolite 2-hydroxyglutarate. Ivosidenib, enasidenib, and their role in glioma and AML research and therapy.
Honest assessment of curcumin and synthetic analogs like EF24 and FLLL32. Why natural curcumin has limited bioavailability and how research-grade derivatives improve selectivity.
Natural product kinase inhibitors from staurosporine to midostaurin. How evolution inspired drug discovery and why natural products remain essential research tools.
Explore ROS1 inhibitors from crizotinib to next-generation compounds like entrectinib and lorlatinib. Learn how researchers select ROS1 tools and understand resistance mechanisms.
Review 2024-2025 FDA kinase inhibitor approvals including MEK, FAK, JAK, ROS1, HER2 inhibitors and emerging trends for cancer research.
BRAF V600E inhibitors like vemurafenib and dabrafenib are highly effective but suffer from paradoxical pathway activation. Discover how paradox breaker RAF inhibitors overcome this limitation and what they reveal about kinase inhibitor design principles.
Focal adhesion kinase (FAK) drives cancer invasion and metastasis. Explore how first-generation FAK inhibitors work, their clinical progress, and how emerging PROTAC degraders overcome their limitations. Learn about combination strategies with immunotherapy.
Tumor-associated macrophages suppress anti-cancer immunity. CSF1R inhibitors like pexidartinib reprogram these immunosuppressive cells and enhance T cell infiltration. Explore the biology, research compounds, and combination strategies.
